Bristol To Devote $125 Mil. To Develop Medarex' Metastatic Melanoma Agent

Bristol adds Phase III anti-CTLA-4 product MDX-010 to its franchise as several of its oncologics are exposed to generic competition. Medarex cites upside potential as a reason for entering into the collaboration with Bristol.